Drugs / BP1.4979
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07074002 | Sep 2025 → Dec 2026 expected | essential tremor | Bioprojet | Recruiting | No outcome recorded |
| Phase 2 | NCT07047404 | Sep 2025 → Dec 2026 expected | premature ejaculation | Bioprojet | Recruiting | No outcome recorded |
| Phase 2 | NCT05118906 | Mar 2022 → Aug 2025 | binge eating disorder | Bioprojet | Completed | No outcome recorded |
| Phase 2 | NCT03345953 | Feb 2018 → Apr 2020 | restless legs syndrome | Bioprojet | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01785147 | Feb 2013 → Jul 2014 | nicotine dependence | Bioprojet | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BP1.4979 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01785147 ↗ |
| Modality | Small molecule | — CHEMBL4297484 ↗ |